5α-Reductase Inhibitors Do Not Prevent the Development and Progression of Urothelial Cancer: In Vitro Evidence

September 2020 in “ Bladder cancer ”

Yoshika Nagata, T. Goto, Guiyang Jiang, Yuki Teramoto, Hiroshi Miyamoto

5α-reductase inhibitors dutasteride finasteride epristeride androgen receptor antagonist bicalutamide testosterone 5α-RIs Propecia Avodart

From the encyclopedia

Dutasteride →

Heavy duty finasteride that comes with higher risks

Finasteride →

Frontline, gold standard treatment for combatting androgenic alopecia

Bicalutamide →

a nonsteroidal anti-androgen, most commonly used orally for women

Studysummary In this study, 5α-reductase inhibitors were found to have no significant impact on preventing tumorigenesis or progression in in vitro models of urothelial cancer. Our plain-language summary of this paper — not a Tressless recommendation.

The document from December 14, 2020, presents findings from an in vitro study which determined that 5α-reductase inhibitors (5α-RIs) such as dutasteride, finasteride, and epristeride do not prevent the development or progression of urothelial cancer. The study used a human non-neoplastic urothelial cell line and human bladder cancer lines to assess the effects of these drugs. While the androgen receptor antagonist bicalutamide significantly inhibited the proliferation of AR-positive bladder cancer cells, the 5α-RIs did not have a significant effect on inhibiting cell migration or the neoplastic transformation of cells treated with testosterone. The conclusion drawn was that 5α-RIs, even at high doses, do not impact the prevention of tumorigenesis or tumor progression in urothelial cancer.

View this study on content.iospress.com →

Discuss this study in the Community →

Research cited in this study

9 / 9 results

research Possible Role of 5-Alpha Reductase Inhibitors in Non-Invasive Bladder Urothelial Neoplasm: Multicentre Study

4 citations , December 2019 in “Minerva Urology and Nephrology”

This study found that patients with non-muscle invasive bladder cancer who were treated with 5-alpha reductase inhibitors had lower recurrence rates and higher recurrence-free survival rates compared to untreated patients.

research Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?

9 citations , August 2019 in “Clinical genitourinary cancer”

This study suggests that 5-alpha reductase inhibitors may reduce invasive cancer features and improve survival in men undergoing radical cystectomy for high-grade urothelial carcinoma, although further research is needed to confirm these findings.

research Finasteride Does Not Prevent Bladder Cancer: A Secondary Analysis of the Medical Therapy for Prostatic Symptoms Study

13 citations , May 2018 in “Urologic Oncology: Seminars and Original Investigations”

In this study, researchers found no significant difference in bladder cancer incidence between men treated with finasteride and those given a placebo, suggesting that reduced dihydrotestosterone levels may not impact bladder cancer risk.

research Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors

20 citations , May 2018 in “The Journal of Urology”

This study concluded that 5α-reductase inhibitors were associated with improved survival in men with bladder cancer, while α-blockers showed no effect.

research Expression of AR, 5αR1 and 5αR2 in Bladder Urothelial Carcinoma and Relationship to Clinicopathological Factors

13 citations , September 2017 in “Life sciences”

This study suggests that androgen receptor signaling might regulate cellular behavior in bladder urothelial carcinoma, with decreased receptor and enzyme presence potentially linked to tumor progression.

Evaluation of Bioequivalence of Five 0.1 mg Dutasteride Capsules Compared to One 0.5 mg Dutasteride Capsule: A Randomized Study in Healthy Male Volunteers

research Evaluation of Bioequivalence of Five 0.1 mg Dutasteride Capsules Compared to One 0.5 mg Dutasteride Capsule: A Randomized Study in Healthy Male Volunteers

3 citations , January 2015 in “Journal of drug assessment”

This study found that five 0.1 mg dutasteride capsules are bioequivalent to one 0.5 mg dutasteride capsule in healthy adult males under fasting conditions, and both were well tolerated.

research SRD5A3 Is Required for Converting Polyprenol to Dolichol and Is Mutated in a Congenital Glycosylation Disorder

260 citations , July 2010 in “Cell”

This study identifies mutations in the SRD5A3 gene as a cause of a new type of congenital disorder of glycosylation, impacting mental, ophthalmologic, and cerebellar functions.

research An Overview on 5α-Reductase Inhibitors

219 citations , October 2009 in “Steroids”

5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.

research Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor

408 citations , May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism”

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.